Geoffrey M. Parker - 24 Jan 2025 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/Earl Douglas, Attorney-in-Fact
Issuer symbol
ALLO
Transactions as of
24 Jan 2025
Net transactions value
$0
Form type
4
Filing time
28 Jan 2025, 20:15:11 UTC
Previous filing
23 Oct 2024
Next filing
05 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $0 +173,913 +15% $0.000000 1,305,901 24 Jan 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to buy) Award $0 +614,844 $0.000000 614,844 24 Jan 2025 Common Stock 614,844 $1.94 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter.